Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

OGN

Organon & Co

Apr 10 • 04:00PM ET

8.83

+1.92 27.79 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Apr 10, 7:30 AMReports of Sun Pharma's $12B binding bid for Organon drive ~20% premarket surge.

Peers: PFE MRK JNJ NVS ABBV LLY BMY GSK AZN-D BIIB

| Held by: IJR VTI VB VBR FXH VXF SPSM IJS SLYV SCHA

Scroll to Statements

Index	-	P/E	12.32	EPS (ttm)	0.72	Insider Own	0.46%	Shs Outstand	260.32M	Perf Week	38.84%
Market Cap	2.30B	Forward P/E	2.37	EPS next Y	3.72	Insider Trans	5.78%	Shs Float	259.11M	Perf Month	37.97%
Enterprise Value	10.52B	PEG	0.89	EPS next Q	0.83	Inst Own	76.35%	Short Float	8.54%	Perf Quarter	8.61%
Income	187.00M	P/S	0.37	EPS this Y	-5.23%	Inst Trans	-1.41%	Short Ratio	4.59	Perf Half Y	-13.77%
Sales	6.22B	P/B	3.06	EPS next Y	7.30%	ROA	1.44%	Short Interest	22.13M	Perf YTD	23.15%
Book/sh	2.89	P/C	4.00	EPS next 5Y	2.66%	ROE	30.56%	52W High	13.24 -33.33%	Perf Year	-22.75%
Cash/sh	2.21	P/FCF	4.27	EPS past 3/5Y	-41.56% -39.04%	ROIC	1.97%	52W Low	5.69 55.18%	Perf 3Y	-62.98%
Dividend Est.	0.06 (0.73%)	EV/EBITDA	6.59	Sales past 3/5Y	0.23% -1.00%	Gross Margin	53.59%	Volatility	10.14% 5.61%	Perf 5Y	-
Dividend TTM	0.08 (0.91%)	EV/Sales	1.69	EPS Y/Y TTM	-78.50%	Oper. Margin	20.01%	ATR (14)	0.49	Perf 10Y	-
Dividend Ex-Date	Feb 23, 2026	Quick Ratio	1.23	Sales Y/Y TTM	-2.92%	Profit Margin	3.01%	RSI (14)	75.08	Recom	3.50
Dividend Gr. 3/5Y	-32.79% -	Current Ratio	1.82	EPS Q/Q	-287.86%	SMA20	40.43%	Beta	0.69	Target Price	9.67
Payout	47.41%	Debt/Eq	11.70	Sales Q/Q	-5.34%	SMA50	26.15%	Rel Volume	8.16	Prev Close	6.91
Employees	10000	LT Debt/Eq	11.63	Earnings	Feb 12 AMC	SMA200	5.21%	Avg Volume	4.82M	Price	8.83
IPO	May 14, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.34% -1.81%	Trades		Volume	39,328,872	Change	27.79%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Underweight	$7.50
Oct-27-25	Downgrade	Piper Sandler	Overweight → Underweight	$5
May-02-25	Downgrade	Evercore ISI	Outperform → In-line
Sep-06-24	Downgrade	JP Morgan	Neutral → Underweight	$18 → $20
Nov-03-23	Downgrade	Goldman	Buy → Neutral	$33 → $16
Sep-21-23	Initiated	Barclays	Overweight	$28
Mar-16-23	Initiated	Raymond James	Outperform	$33
Oct-14-22	Downgrade	BofA Securities	Neutral → Underperform	$27 → $25
Sep-06-22	Upgrade	Piper Sandler	Neutral → Overweight	$37 → $34
Aug-05-22	Downgrade	BofA Securities	Buy → Neutral	$40 → $37
Apr-27-22	Initiated	Goldman	Buy	$40
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$35
Oct-07-21	Initiated	Piper Sandler	Neutral	$35
Sep-01-21	Initiated	BofA Securities	Buy	$43
Jul-22-21	Initiated	Citigroup	Buy	$35
Jun-15-21	Initiated	JP Morgan	Neutral	$38
Jun-11-21	Initiated	Morgan Stanley	Equal-Weight	$33
Jun-10-21	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Apr-10-26 02:43PM	Organon Jumps 25% As Report Cites $12 Billion Sun Pharma Offer (GuruFocus.com) +27.79%
10:01AM	This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. (Barrons.com)
09:25AM	This Womens Healthcare Stock Is Up 15% on Reports of a Takeover In the Works (Investopedia)
08:46AM	Organon climbs on report of takeover bid and more stocks on the move (MarketWatch)
Mar-27-26 08:00AM	Organon Debuts New Analysis of VTAMA (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age (Business Wire)
07:01AM	Loading…
Mar-24-26 07:01AM	Organon: A High Cash Yield Hidden Behind Patent Fatigue (GuruFocus.com)
Mar-02-26 12:59PM	OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis (Zacks)
Feb-27-26 08:00AM	New Analysis of Organons VTAMA (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis (Business Wire)
Feb-23-26 04:37PM	Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% (Insider Monkey)
07:30AM	Organon Enters into Agreement to License MIUDELLA, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device (Business Wire)
Feb-19-26 12:39AM	5 Revealing Analyst Questions From Organon's Q4 Earnings Call (StockStory)
Feb-13-26 01:09AM	Organon & Co. Q4 Earnings Call Highlights (MarketBeat)
12:34AM	OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook (StockStory)
Feb-12-26 04:32PM	Organon & Co. Q4 2025 Earnings Call Summary (Moby) -8.19%
04:04PM	Organon & Co (OGN) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
10:30AM	Loading…
10:30AM	Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:50AM	Organon (OGN) Misses Q4 Earnings and Revenue Estimates (Zacks)
08:01AM	Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations (StockStory)
07:51AM	Organon: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 (Business Wire)
Feb-10-26 10:05PM	Organon Earnings: What To Look For From OGN (StockStory)
Feb-02-26 05:50PM	Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Jan-29-26 01:28PM	Organon Completes Divesture of JADA System to Laborie Medical (Zacks)
Jan-28-26 12:45PM	Organon Completes Divestiture of JADA System to Laborie (Business Wire)
Jan-27-26 05:50PM	Organon (OGN) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-22-26 06:46AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-21-26 06:00PM	Organon (OGN) Outperforms Broader Market: What You Need to Know (Zacks)
Jan-20-26 03:10PM	Why Are Organon (OGN) Shares Soaring Today (StockStory) +7.99%
11:04AM	Organon Secures FDA Approval Extending NEXPLANON Use to Five Years (Zacks)
10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
09:12PM	Loading…
Jan-16-26 09:12PM	Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque (Business Wire)
08:53AM	JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency (Pharmaceutical Technology)
Jan-15-26 05:50PM	Organon (OGN) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jan-14-26 06:00PM	Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Jan-08-26 01:30AM	Organon Enters into a Commercialization Agreement for Daiichi Sankyos Nilemdo in France, Denmark, Iceland, Sweden, Finland and Norway (Business Wire)
Jan-05-26 06:00PM	Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing (Zacks) +8.47%
Dec-24-25 09:00AM	Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock (Zacks)
Dec-22-25 05:50PM	Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Dec-12-25 09:00AM	Is Trending Stock Organon & Co. (OGN) a Buy Now? (Zacks)
Dec-09-25 04:01PM	Why Organon (OGN) Shares Are Trading Lower Today (StockStory)
Dec-01-25 09:00AM	Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Nov-30-25 11:03PM	Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-25-25 10:32PM	Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks (StockStory) +6.37%
07:30AM	Organon To Present at the Piper Sandler 37th Annual Healthcare Conference (Business Wire)
Nov-18-25 09:00AM	Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Nov-17-25 01:14PM	Henlius and Organon score first US Perjeta biosimilar approval (Pharmaceutical Technology)
05:30AM	Henlius and Organon Announce US FDA Approval of POHERDY (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US (Business Wire)
12:34AM	The 5 Most Interesting Analyst Questions From Organon's Q3 Earnings Call (StockStory)
Nov-11-25 12:50PM	Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends (Insider Monkey)
12:26PM	Organon (OGN) Stock Trades Down, Here Is Why (StockStory)
12:31AM	OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration (StockStory)
Nov-10-25 04:01PM	Organon & Co (OGN) Q3 2025 Earnings Call Highlights: Strong Biosimilars Performance Amidst ... (GuruFocus.com) +13.72%
01:30PM	Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
10:06AM	Laborie inks $465M deal to buy post-childbirth device from Organon (MedTech Dive)
08:45AM	Organon (OGN) Q3 Earnings and Revenues Beat Estimates (Zacks)
08:01AM	Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q3 (StockStory)
07:45AM	Organon: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Organon Reports Results for the Third Quarter Ended September 30, 2025 (Business Wire)
Nov-08-25 10:02PM	Organon (OGN) Reports Earnings Tomorrow: What To Expect (StockStory)
Nov-07-25 12:50PM	Organon divests JADA system to Laborie in $465m deal (Medical Device Network)
07:30AM	Organon Announces Agreement to Divest its JADA System for Up to $465 Million to Laborie (Business Wire)
Nov-06-25 07:30AM	Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025 (Business Wire) +5.17%
Oct-30-25 04:56AM	Jim Cramer's "Worst Stock Ever" Might Be Organon (OGN) (Insider Monkey)
Oct-28-25 03:21PM	Why Organon (OGN) Stock Is Down Today (StockStory) -5.67%
Oct-27-25 01:30PM	Organon CEO stands down amid contraceptive sales malpractice probe (Medical Device Network) -22.93%
01:26PM	This Drugmaker Made 'Improper' Sales to Meet Guidance. The Stock Plummets 25%. (Barrons.com)
Oct-23-25 05:50PM	Organon (OGN) Laps the Stock Market: Here's Why (Zacks)
10:00AM	Organon (OGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-21-25 09:00AM	Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Oct-17-25 05:50PM	Organon (OGN) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Oct-16-25 06:00PM	Organon (OGN) Dips More Than Broader Market: What You Should Know (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-08-25 11:32PM	Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks (StockStory)
09:00AM	Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know (Zacks)
Oct-06-25 06:00PM	Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
12:10PM	Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
12:02AM	3 Reasons to Avoid OGN and 1 Stock to Buy Instead (StockStory)
Sep-29-25 05:50PM	Organon (OGN) Outperforms Broader Market: What You Need to Know (Zacks)
Sep-25-25 06:00PM	Here's Why Organon (OGN) Fell More Than Broader Market (Zacks)
Sep-24-25 09:00AM	Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock (Zacks)
Sep-19-25 05:50PM	Organon (OGN) Stock Dips While Market Gains: Key Facts (Zacks)
06:00AM	European Commission (EC) Approves Henlius and Organons BILDYOS (denosumab) and BILPREVDA (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively (Business Wire)
Sep-12-25 09:00AM	Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Sep-11-25 11:55AM	Why Organon (OGN) Stock Is Trading Up Today (StockStory)
12:35AM	3 Stocks Under $50 We Find Risky (StockStory)
Sep-10-25 05:50PM	Organon (OGN) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Sep-02-25 05:30AM	US Food and Drug Administration (FDA) Approves Henlius and Organons BILDYOS (denosumab-nxxp) and BILPREVDA (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively (Business Wire)
Aug-29-25 05:04AM	Organon & Co. (OGN) Advances VTAMA Cream, Strengthens Women's Health Portfolio (Insider Monkey)
Aug-25-25 09:00AM	Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Aug-13-25 12:10AM	OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter (StockStory)
12:02AM	5 Must-Read Analyst Questions From Organon's Q2 Earnings Call (StockStory)
Aug-12-25 09:00AM	Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know (Zacks)
08:00AM	Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire)
Aug-08-25 11:40AM	OGN vs. HQY: Which Stock Is the Better Value Option? (Zacks)
Aug-07-25 01:01PM	Organon & Co. (OGN) Reports Q2 2025 Results (Insider Monkey)
Aug-06-25 12:22PM	Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings (Insider Monkey)
Aug-05-25 11:00AM	Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -13.13%
08:45AM	Organon (OGN) Beats Q2 Earnings and Revenue Estimates (Zacks)

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Drinane Juliana Papa	Interim Head of Mfg & Supply	Mar 31 '26	Option Exercise	0.00	16,451	0	36,687	Apr 02 04:26 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Mar 31 '26	Option Exercise	0.00	13,431	0	34,867	Apr 02 04:18 PM
Karp Daniel	Executive VP, Corp. Dev.	Mar 31 '26	Option Exercise	0.00	18,053	0	71,653	Apr 02 04:17 PM
Stahler Rachel A	Chief Information Officer	Mar 31 '26	Option Exercise	0.00	18,867	0	120,322	Apr 02 04:14 PM
WALSH MATTHEW M	Chief Financial Officer	Mar 31 '26	Option Exercise	0.00	33,593	0	220,126	Apr 02 04:13 PM
Falcione Aaron	Chief Human Resources Officer	Mar 31 '26	Option Exercise	0.00	17,925	0	105,265	Apr 02 04:11 PM
Weaver Kirke	Gen. Counsel & Corp. Secy.	Mar 31 '26	Option Exercise	0.00	18,513	0	96,147	Apr 02 04:09 PM
Nisita Vittorio	Head of Global Business Svcs	Mar 31 '26	Option Exercise	0.00	13,000	0	73,494	Apr 02 04:07 PM
Holzbaur Lynette	SVP and Corporate Controller	Mar 31 '26	Option Exercise	0.00	10,967	0	28,316	Apr 02 04:06 PM
Morrissey Joseph T. Jr.	Interim CEO	Mar 31 '26	Option Exercise	0.00	24,584	0	127,907	Apr 02 04:02 PM
Stahler Rachel A	Chief Information Officer	Mar 29 '26	Option Exercise	0.00	8,200	0	106,510	Mar 31 04:16 PM
Holzbaur Lynette	SVP and Corporate Controller	Mar 29 '26	Option Exercise	0.00	5,319	0	19,995	Mar 31 04:15 PM
Karp Daniel	Executive VP, Corp. Dev.	Mar 29 '26	Option Exercise	0.00	14,184	0	60,853	Mar 31 04:14 PM
Weaver Kirke	Gen. Counsel & Corp. Secy.	Mar 29 '26	Option Exercise	0.00	7,757	0	81,611	Mar 31 04:12 PM
Nisita Vittorio	Head of Global Business Svcs	Mar 29 '26	Option Exercise	0.00	5,762	0	64,046	Mar 31 04:11 PM
Drinane Juliana Papa	Interim Head of Mfg & Supply	Mar 29 '26	Option Exercise	0.00	7,979	0	25,154	Mar 31 04:10 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Mar 29 '26	Option Exercise	0.00	8,865	0	23,909	Mar 31 04:09 PM
Falcione Aaron	Chief Human Resources Officer	Mar 29 '26	Option Exercise	0.00	8,422	0	92,531	Mar 31 04:08 PM
WALSH MATTHEW M	Chief Financial Officer	Mar 29 '26	Option Exercise	0.00	15,071	0	195,822	Mar 31 04:06 PM
Morrissey Joseph T. Jr.	Interim CEO	Mar 29 '26	Option Exercise	0.00	9,752	0	108,323	Mar 31 04:05 PM
COX CARRIE SMITH	Executive Chair	Nov 12 '25	Buy	7.67	65,400	501,755	77,869	Nov 13 04:05 PM
Drinane Juliana Papa	Interim Head of Mfg & Supply	Nov 07 '25	Option Exercise	0.00	3,626	0	18,417	Nov 12 05:48 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Nov 07 '25	Option Exercise	0.00	6,446	0	31,223	Nov 10 04:14 PM
Holzbaur Lynette	SVP and Corporate Controller	Nov 07 '25	Option Exercise	0.00	2,417	0	15,365	Nov 10 04:04 PM
Holzbaur Lynette	SVP and Corporate Controller	Nov 05 '25	Option Exercise	0.00	3,037	0	13,814	Nov 06 04:11 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Aug 11 '25	Option Exercise	0.00	11,519	0	28,899	Aug 12 04:05 PM
COX CARRIE SMITH	Director	May 14 '25	Buy	8.07	12,469	100,591	12,469	May 15 04:09 PM
Falcione Aaron	Chief Human Resources Officer	May 07 '25	Buy	8.77	5,500	48,235	62,974	May 07 12:13 PM
Weaver Kirke	Gen. Counsel & Corp. Secy.	May 06 '25	Buy	9.21	8,045	74,054	52,489	May 07 12:12 PM
Karp Daniel	Executive VP, Corp. Dev.	May 06 '25	Buy	8.24	3,500	28,828	46,669	May 07 12:09 PM
WALSH MATTHEW M	Chief Financial Officer	May 05 '25	Buy	8.82	11,400	100,548	144,484	May 06 01:59 PM
Ali Kevin	Chief Executive Officer	May 05 '25	Buy	8.80	34,000	299,370	282,731	May 06 01:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OGN

Organon & Co

Upgrade your Finviz experience